The natriuretic peptide system plays an active role in the regulation of fluid balance and systemic vascular resistance. Peptides of the natriuretic system produced through recombinant DNA technology are now available for clinical use including both atrial natriuretic peptide (ANP) and brain-type natriuretic peptide (BNP). Assays of BNP are available and may be used for both diagnostic and prognostic purposes in various clinical scenarios. The basic physiology of the natriuretic peptide system is presented, applications of BNP monitoring as a diagnostic tool are reviewed, and reports regarding the use of recombinant BNP in the pediatric population are discussed.
Marshall J., Berkenbosch JW, Russo P., Tobias JDPreliminary experience with nesiritide in the pediatric population . J Intensive Care Med. 2004;19(3):164-170.
2.
Smith T., Rosen D., Russo P., et al. Nesiritide during extracorporeal membrane oxygenation. Paediatr Anaeth. 2005;15(2):152-157.
3.
Wheeler A., Tobias JDNesiritide in a pediatric oncology patient with renal insufficiency and myocardial dysfunction following septic shock. Pediatr Hematol Oncol . 2005;22(4):323-333.
4.
Simsic JM, Scheurer M., Tobias JD, et al. Perioperative effects and safety of nesiritide following cardiac surgery in children. J Intensive Care Med. 2006;21(1):22-26.
5.
Rana R., Vlahakis NE, Daniels CE, et al. B-type natriuretic peptide in the assessment of acute lung injury and cardiogenic pulmonary edema. Crit Care Med. 2006;34(7):1941-1946.
6.
Mir TS, Haun C., Lilje C., et al. Utility of N-terminal brain natriuretic peptide plasma concentrations in comparison to lactate and troponin in children with congenital heart disease following open heart surgery. Pediatr Cardiol. 2006:27(2):209-216.
7.
Shih CY, Sapru A., Oishi P., et al. Alterations in b-type natriuretic peptide levels after repair of congenital heart defects: a potential perioperative marker. J Thorac Cardiovasc Surg. 2006;131(3): 632-636.
8.
de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H.A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981 ;28(1):89-94.
9.
deBold JAAtrial natriuretic factor of the heart: studies on isolation and properties . Proc Soc Exp Biol Med.1982;170(2):133-138.
10.
Flynn TG, de Bold ML, de Bold AJThe amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun. 1983 ;117(3):859-865.
11.
Forssmann W. , Meyer M., Forssmann K.The renal urodilantin system: clinical implications . Cardiovasc Res. 2001;51(3):450-462.
12.
Mukoyama M. , Nakao K., Hosoda K., et al. Brain natriuretic peptide as novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87(4):1402-1412.
13.
Chen HH, Burnett JC Jr.C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol. 1998 ;32(suppl3):S22-S28.
14.
Schirger JA , Heublein DM, Chen HH, et al. Presence of Dendroaspis natriuretic-peptide like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc. 1999;74(2):126-130.
15.
Lainchbury JG, Lisy O., Burnett JC Jr, Meyer DM, Redfield MMActions of a novel synthetic natriuretic peptide on hemodynamics and ventricular function in the dog. Am J Physiol Regul Integr Comp Physiol. 2002;282(4):R993-R998.
16.
Tamura N., Ogawa Y., Chusho H., et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000;97(8):4239-4244.
17.
Maisel AS, Krishnaswamy P., Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167.
18.
Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in evaluation and management of acute dyspnea. N Engl J Med.2004;350(7):647-654.
19.
Bajwa EK, Januzzi JL, Gong MN, Thompson BT, Christiani DCPrognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome. Crit Care Med . 2008;36(8):2322-2327.
20.
Tung RH, Garcia C., Morss AM, et al. Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med. 2004;32(8):1643-1647.
21.
Machado RF, Anthi A., Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA. 2006;296(3):310-318.
22.
Koulouri S. , Acherman RJ, Wong PC, Chan LS, Lewis ABUtility of B-type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol. 2004;25(4):341-346.
23.
Maher KO, Reed H., Cuadrado A., et al. B-type natriuretic peptide in the emergency diagnosis of critical heart disease in children. Pediatrics. 2008 ;121(6):e1484-1488.
24.
Cohen S., Springer C., Avital A., et al. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease? Pediatrics. 2005; 115:1347-1350.
25.
Tan LH, Jefferies JL, Liang JF, et al. Concentrations of brain natriuretic peptide in the plasma predicts outcomes of treatment of children with decompensated heart failure admitted to the intensive care unit. Cardiol Young. 2007;17(4):397-406.
26.
Reynolds EW , Ellington JG, Vranicar M., Bada HSBrain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics. 2004;114(5): 1297-1304.
27.
Puddy YF, Amirmansour C., Williams AF, Singer DRJ.Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci. 2002; 103(1):75-77.
Muta H., Ishii M., Maeno Y., Akagi T., Kato H.Quantitative evaluation of the changes in plasma concentrations of cardiac natriuretic peptides before and after transcatheter closure of atrial septal defect. Acta Paediatr. 2002;91(6):649-652.
Hsu JH, Oishi PE, Keller RL, et al. Perioperative B-type natriuretic peptide levels predict outcome after bidirectional cavopulmonary anastomosis and total cavopulmonary connection . J Thorac Cardiovasc Surg. 2008;135(4):746-753.
32.
Gessler P., Knirsch W., Schmitt B., Rousson V., von Eckardstein A.Prognostic value of plasma N-terminal pro-brain natriuretic peptide in children with congenital heart defects and open-heart surgery. J Pediatr . 2006;148(3):372-376.
33.
Pietrzak R. , Werner B.Usefulness of NT-proBNP in assessment of right ventricular function in children after tetralogy of Fallot correction-a preliminary study. Kardiol Pol.2009;67(4):378-383.
34.
Chikovani O. , Hsu JH, Keller R., et al. B-type natriuretic peptide levels predict outcomes for children on extracorporeal life support after cardiac surgery. J Thor Cardiovasc Surg. 2007;134(5): 1179-1187.
35.
Huang SC, Wu ET, Ko WJ, et al. Clinical implication of blood levels of B-type natriuretic peptide in pediatric patients on mechanical circulatory support. Ann Thor Surg. 2006;81(6): 2267-2272.
36.
Falkensammer CB, Heinle JS, Chang ACSerial plasma BNP levels in assessing inadequate left ventricular decompression on ECMO. Pediatr Cardiol. 2008;29(4):808-811.
37.
Lindblade CL , Chun DS, Darragh RK, et al. Value of plasma B-type natriuretic peptide as a marker for rejection in pediatric heart transplant recipients . Am J Cardiol. 2005;95(7):909-911.
38.
Kaski JP, Tome-Esteban MT, Mead-Regan SJ, et al. B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy. Heart. 2008 ;94(10):1307-1311.
39.
Hayakawa H. , Komade Y., Hirayama M., et al. Plasma level of natriuretic peptides in relation to doxorubicin-induced cardiomyopathy and cardiac function in children with cancer. Med Pediatr Oncol. 2001 ;37:4-9.
40.
Pinarli FG, Oguz A., Tunaoglu S., Karadeniz C., Gökçora N., Elbeg S.Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer. 2005; 44(4):370-377.
41.
Lieppman K. , Kramer-Clark L., Tobias JDPlasma B-type natriuretic peptide monitoring to evaluate cardiovascular function prior to organ procurement in patients with brain death. Pediatr Anesth. 2008;18(9):852-856.
42.
Sviri GE, Soustiel JF, Zaaroor M.Alteration in brain natriuretic peptide (BNP) plasma concentration following severe traumatic brain injury. Acta Neurochir. 2006;148(5):529-533.
43.
Kirchoff C. , Stegmaier J., Bogner V., et al. Intrathecal and systemic concentration of NT-proBNP in patients with severe traumatic brain injury. J Neurotrauma. 2006;23(6):943-949.
44.
Obi T., Takatsu M., Konishi T., Mizoguchi K., Nishimura Y.Secretion of natriuretic peptides caused by an epileptic attack. Acta Neurol Scand. 2002;106(4):225-228.
45.
Rauchenzauner M., Haverlandt E., Foerster S., et al. Brain-type natriuretic peptide secretion following febrile and afebrile seizures-a new marker in children epilepsy . Epilepsia. 2007;48(1): 101-106.
46.
Charpentier J., Luyt CE, Fulla Y., et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis . Crit Care Med. 2004;32(3):660-665.
47.
Rudiger A., Gasser S., Fischler M., et al. Comparable increases of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med. 2006;34: 2140-2144.
48.
Maeder M., Ammann P., Kiowski W., Rickli H.B-type natriuretic peptide in patients with sepsis and preserved left ventricular ejection fraction. Eur J Heart Fail. 2005;7(7):1164-1167.
49.
Bar S., Swiggum E., Straatman L., Ignaszewski A.Nonheart failure associated elevation of amino-terminal pro-brain natriuretic peptide in the setting of sepsis. Can J Cardiol . 2006;22(3):263-266.
50.
McClean AS, Poh G., Huang SJThe effect of acute fluid loading on plasma B-type natriuretic peptide levels in a septic shock patient. Anaesth Intensive Care. 2005;33(4):528-530.
51.
Tung RH, Garcia C., Morss AM, et al. Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med. 2004;32(8):1643-1647.
52.
Pirracchio R. , Deye N., Lukaszewica AC, et al. Impaired B-type natriuretic peptide clearance in human septic shock. Crit Care Med. 2008;36(9):2542-2546.
53.
Domico M., Liao P., Anas N., Mink RBElevation of brain natriuretic peptide levels in children with septic shock . Crit Care Med. 2008;9(5):478-483.
54.
Costello JM , Backer CL, Checchia PA, Mavroudis C., Seipelt RG, Goodman DMAlterations in the natriuretic hormone system related to cardiopulmonary bypass in infants with congestive heart failure . Pediatr Cardiol. 2004;25(4):347-353.
55.
Colucci WS, Elkayam U., Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med.2000;343:246-253.
56.
Publication Committee for VMAC Investigators.Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287(12):1531-1540.
57.
Marcus LS, Hart D., Packer M., et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1996;94(12): 3184-3189.
58.
Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JNAcute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Ann Intern Med. 1985;103(1):1-6.
59.
Gottlieb SS , Brater C., Thomas I., et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002; 105(11):1348-1353.
60.
Lombardi R. , Ferreiro A., Servetto C.Renal function after cardiac surgery: adverse effect of furosemide. Renal Fail . 2003;25(5): 775-786.
61.
Jeffries JL , Denfield SW, Price JF, et al. A prospective evaluation of nesiritide in the treatment of pediatric heart failure. Pediatr Cardiol . 2006;27(4):402-407.
62.
Jefferies JL , Price JF, Denfield SW, et al. Safety and efficacy of nesiritide in pediatric heart failure. J Cardiac Fail. 2007;13(7): 541-548.
63.
Ryan A., Rosen DA, Tobias JDPreliminary experience with nesiritide in pediatric patients less than 12 months of age. J Intensive Care Med. 2008;23(5):321-328.
64.
Sehra R., Underwood K.Nesiritide use for critically ill children awaiting cardiac transplantation . Pediatr Cardiol. 2006;27(1):47-50.
65.
Mahle WT, Cuadrado AR, Kirshbom PM, et al. Nesiritide in infants and children with congestive heart failure . Pediatr Crit Care Med. 2005;6:543-546.
66.
Simsic JM, Reddy VS, Kanter KR, et al. Use of nesiritide (human b-type natriuretic peptide) in infants following cardiac surgery. Pediatr Cardiol. 2004;25:668-670.
67.
Sehra R., Underwood K.Nesiritide use in critically for critically ill children awaiting cardiac transplantation. Pediatr Cardiol. 2006; 27(1):47-50.
68.
Simsic JM, Mahle WT, Cuadrado A., et al. Hemodynamic effects and safety of nesiritide in neonates with heart failure. J Intensive Care Med. 2009;23:390-389.
69.
Reynolds EW , Conely ET, Vranicar M.Nesiritide for the treatment of pulmonary hypertension and cor pulmonale in an infant. Pediatr Cardiol . 2007;28(3):229-233.
70.
Wheeler AD, Tobias JDNesiritide in a pediatric oncology patient with renal insufficiency and myocardial dysfunction following septic shock. Pediatr Hemat Oncol. 2005;22(4):323-333.
71.
Burger AJ, Horton DP, LeJemtel T., et al. Effect of nesiritide (b-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J . 2002;144(6):1102-1108.
72.
Wang DJ, Dowling TC, Meadows D., et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation . 2004;110:1620-1625.
73.
Sackner-Bernstein JD, Skopicki HA, Aaronson KDRisk of worsening renal function with nesiritide in patients with acutely decompensated heart failure . Circulation . 2005;111(12):1487-1491.
74.
Mentzer RM, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol. 2007;49(6): 716-726.
75.
McKown Dyke C., Bhatia D., Aronson S., Moazami N., Mentzer RM Jr.Perioperative nesiritide and possible renal protection in patients with moderate to severe kidney dysfunction. J Thor Cardiov Surg. 2008;136(5):1369-1370.
76.
Yosdhibayashi M., Kamiya T., Saito Y., et al. Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increased after birth. Eur J Endocrinol. 1995;133(2):207-209.
77.
Mir TS, Marohn S., Laer S., Eiselt M., Grollmus O., Weil J.Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics. 2002;110(6):e76.
78.
Mir TS, Flato M., Falkenberg J., et al. Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents, and young adults: effect of age and gender . Pediatr Cardiol. 2006; 27(1):73-77.
79.
Chenevier-Gobeaus C., Classens YE, Voyer S., Desmoulins D., Ekindjian OGInfluence of renal function on N-terminal probrain natriuretic peptide in patients admitted for dyspnea in the emergency department: comparison with brain natriuretic peptide. Clin Chim Acta. 2005;361(1-2):167-175.
80.
Nishiyama K. , Tsutamoto T., Tanaka T., et al. Plasma NT-proBNP as a more reliable biomarker of endogenous cardiac natriuretic peptides than BNP during carpertidie infusions. Int Heart J.2009;50(2):183-190.
81.
Mueller T., Gegenhuber A., Poelz W., Haltmayer M.Biochemical diagnosis of impaired left ventricular ejection fraction-comparison of the diagnostic accuracy of brain natriuretic peptide and amino terminal proBNP. Clin Chem Lab Med. 2004;42(2): 159-163.
82.
Hammerer-Lercher A., Neubauer E., Muller S., Pachinger O., Puschendorf B., Mair J.Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction . Clin Chim Acta. 2001;310(2):193-197.
83.
Moe GW, Howlett J., Januzzi JL, et al. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure. Circulation. 2007;115(24): 3103-3110.
